Human Cytochrome P450 19A1(CYP19A1) ELISA kit

Code CSB-EL006394HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name cytochrome P450, family 19, subfamily A, polypeptide 1
Alternative Names ARO ELISA Kit; ARO1 ELISA Kit; Aromatase ELISA Kit; CP19A_HUMAN ELISA Kit; CPV1 ELISA Kit; CYAR ELISA Kit; CYP19 ELISA Kit; Cyp19a1 ELISA Kit; CYPXIX ELISA Kit; Cytochrome P-450AROM ELISA Kit; Cytochrome P450 19A1 ELISA Kit; Cytochrome P450; family 19; subfamily A; polypeptide 1 ELISA Kit; Cytochrome P450; subfamily XIX (aromatization of androgens) ELISA Kit; Estrogen synthase ELISA Kit; Estrogen synthetase ELISA Kit; Flavoprotein linked monooxygenase ELISA Kit; MGC104309 ELISA Kit; Microsomal monooxygenase ELISA Kit; OTTHUMP00000162543 ELISA Kit; OTTHUMP00000198350 ELISA Kit; P 450AROM ELISA Kit
Abbreviation CYP19A1
Uniprot No. P11511
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 26.7 pg/mL-1000 pg/mL
Sensitivity 6.7 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Metabolism
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<15%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<15%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human CYP19A1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 90  
Range % 85-94  
1:2 Average % 94  
Range % 90-99  
1:4 Average % 99  
Range % 95-103  
1:8 Average % 85  
Range % 80-89  
The recovery of human CYP19A1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 95 90-100  
EDTA plasma (n=4) 91 86-95  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected  
1000 2.238 2.217 2.228 2.192  
533.3 1.665 1.612 1.639 1.603  
266.7 1.034 1.037 1.036 1.000  
66.7 0.309 0.301 0.305 0.269  
26.7 0.157 0.161 0.159 0.123  
0 0.037 0.034 0.036    
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Background

(From Uniprot)
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene References into Functions
  1. Polymorphism in CYP19A1 is not associated with polycystic ovary syndrome. PMID: 29564739
  2. CYP19A1 was the only gene harboring single nucleotide polymorphisms that were significantly associated with prostate cancer risk PMID: 29228205
  3. CYP19A1 mRNA expression and aromatase activity during syncytialization of primary human villous trophoblast cells at term PMID: 29474975
  4. in postmenopausal women, aromatase activity could be an important determinant of skeletal health. PMID: 29329467
  5. Fungicide ziram may disrupt the placental steroid production. In the present study, we investigated the effects of ziram on steroid formation in human placental cell line JEG-3 cells and on HSD3B1 and aromatase in the human placenta. Ziram did not inhibit progesterone production in JEG-3 cells and HSD3B1 activity at 100muM... ziram is a potent inhibitor of human aromatase. PMID: 28951168
  6. This study demonstrated the existence of an AMH-FOXL2 relationship in hGCs. AMH is capable of increasing both gene and protein expression of FOXL2. Because FOXL2 induces AMH transcription, these ovarian factors could be finely regulated by a positive feedback loop mechanism to preserve the ovarian follicle reserve. PMID: 28660501
  7. The present study reports on the synthesis of pituitary aromatase, its regulation by gonadal steroids, and the physiological roles of aromatase on pituitary endocrine cells. The involvement of aromatase in the pathogenesis of pituitary tumors, mainly prolactinomas, through the auto-paracrine production of estradiol is reviewed. [review] PMID: 29104246
  8. CYP19A1 Val80, a genetic polymorphism related to the conversion of testosterone into estrogen, significantly contributes to individual differences in self-construal and subjective well-being. PMID: 28888137
  9. The findings indicate that the CYP19 alleles rs727479A/C and rs700519C/T might be associated with the pregnancy outcome after assisted reproductive technology in patients with polycystic ovary syndrome. PMID: 29050673
  10. significant prognostic roles of ERalpha, ERbeta and aromatase were discovered in the in prostate cancer specimens of our large multicenter cohort. PMID: 27610593
  11. These studies suggest an association between adiposity, aromatase estrogenic capacity and atrial arrhythmogenicity. PMID: 28822806
  12. Changes in the CYP19A1 expression in adipose tissue stromal vascular fraction cells, induced by free acids, correlated positively with BMI of patients but only in group of obese or overweight women. PMID: 29629743
  13. In conclusion, activated Smad3 proteins can bind to P450arom promoter -705/+87 bp region, responsive to activin A in endometrial stromal cells, which can promote P450arom transcription. PMID: 27920344
  14. polymorphisms not associated with late miscarriage PMID: 28410957
  15. this study illustrated that the brain-specific alternate promoter PI.f derived CYP19 expression can be regulated by DNA methylation. PMID: 28559115
  16. sex steroid hormones and sex hormone binding globulin levels, CYP17 MSP AI (-34T:C) and CYP19 codon 39 (Trp:Arg) variants in children with developmental stuttering PMID: 28992603
  17. RET inhibitors could both impair primary tumor growth and tumor dissemination, thereby providing a potential therapeutic advantage when used in combination with aromatase inhibitors in postmenopausal ER+ breast cancers. PMID: 27602955
  18. We suggest from these studies that overexpression of aromatase in breast tissue and its resultant increase in estradiol levels may contribute to the later development of breast cancer in women with atypical ductal hyperplasia PMID: 28337664
  19. As regards the CYP19A1 variant, genotype 11 (del/del) was more frequent in patients than in controls (OR=1.85; 95% CI 1.06-3.22; P=0.03). PMID: 27145040
  20. C-Jun and CREB are recruited to ESR2 or CYP19A1 promoter by IGF-I stimulation. PMID: 26899323
  21. The results of the present study suggest that AhR stimulates estrogen-dependent progression of breast carcinoma by inducing aromatase expression under some conditions. These results provide new insights on the possible roles of environmental toxins in breast cancer development. PMID: 27900579
  22. In the postmortem study, the amount of PVN aromatase immunoreactivity decreased significantly in the major depressive disorder group compared to the controls PMID: 28024269
  23. Results show that aromatase protein expression is increased in bladder neoplasm tissue and may be associated with advanced tumor stage. PMID: 27324053
  24. Polymorphism of CYP19 is associated with breast cancer. PMID: 28178648
  25. The combination of high carbohydrate intake and the heterozygote (CG) of CYP19A1 rs4441215 showed a higher serum estradiol level in postmenopausal Japanese women. PMID: 28980890
  26. Leptin increased aromatase expression in breast cancer cells, which was correlated with COX-2 upregulation. PMID: 28571770
  27. Immunohistochemical analysis of 221 invasive breast cancer cases indicated that 87.3% (193/221) had at least 5% aromatase positive cells. PMID: 28489882
  28. CYP19A1 amplification caused increased aromatase activity. PMID: 28112739
  29. The reduction of DHT obese homozygotic twins could be linked to its increased degradation by AKR1C2 and HSD11B1, and increased estrogen levels could be linked to increased adiposity-related expression of aromatase in adipose tissue. PMID: 28619249
  30. The authors proposed that NF2 behaves as a protein sensing tissue damage and aromatase-driven local estrogen formation, eventually leading to regulation of stem cells differentiation and tissue repair by liver cancer cells. (Review) PMID: 27289045
  31. The CYP19A1 rs10046 variant T/T favors lower incidence of hot flashes/sweating under exemestane + OFS treatment, suggesting endocrine-mediated effects. PMID: 27825388
  32. R264 polymorphism causes an intrinsic alteration of aromatase activity together with a different consensus for phosphorylation by different kinases, indicating that estrogen production can be different when such mutations are present PMID: 27702664
  33. analysis of how sildenafil inhibits aromatase in human cells by molecular docking simulation PMID: 27616271
  34. 16(beta)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1 PMID: 28065637
  35. Description of a novel functional FSHR expression, where FSH-stimulated CYP19A1 expression and estrogen production in recto-vaginal endometriotic nodules (RVEN) are demonstrated. This locally FSH-induced estrogen production may contribute to the pathology, development, progression, and severity of RVEN . PMID: 27224263
  36. Estradiol synthesis in the hippocampus is regulated by several mechanisms, which are reviewed in this report. The regulation of the activity of aromatase, the final enzyme of estrogen biosynthesis, by Ca(2+) transients, is of particular interest. [review] PMID: 26472556
  37. CYP19A1 activity may contribute to disordered steroidogenesis in female patients with POR mutations as well as in mothers with POR variants carrying a male child PMID: 27032764
  38. The structural and functional importance of estrogen receptor and aromatase in endocrine-responsive and -resistant breast cancers will be discussed in more detail. [review] PMID: 26277097
  39. Aromatase inhibitor treatment significantly increased expression of let-7f in Ishikawa cells and endometrial stroma cells from patients with endometriosis. PMID: 27320036
  40. results show that the Aha1-Hsp90-PKM2/HIF-1alpha axis mediates the induction of aromatase in Li-Fraumeni Syndrome. PMID: 27467582
  41. Data show that the combination of nobiletin (NOB), hesperetin (HES) and letrozole (LET) had no effects on activity and expression of aromatase (cytochrome P450 CYP19) in MCF-7 breast cancer cells. PMID: 28364779
  42. The expression of P450 aromatase corresponds to specific cell morphology in sex cord-stromal tumors, including recurrent tumors. PMID: 26166720
  43. Association study investigated the ESR1, ESR2, and CYP19A1 gene polymorphisms in Chinese migraine patients, data suggested that ESR1 rs2234693 plays a potential role in migraine susceptibility in a Chinese population, especially for menstrually related migraine PMID: 27778160
  44. A novel 568C insertion mutation in CYP19A1 can lead to severe aromatase deficiency. Homozygosity for this mutation is associated with the development of hypoplastic ovaries PMID: 27086564
  45. Significant reduction of CYP19A1 gene expression in Cumulus cells of endometriosis patients may be the result of epigenetic alterations in its regulatory regions, either by DNA methylation or histone modifications. PMID: 27167072
  46. In the bone marrow, cyclin A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen and matrix metalloproteinase MMP9 and promoted the metastatic growth of prostate cancer cells PMID: 26921336
  47. No association of functional polymorphisms in the estrogen metabolism genes CYP19A1 with menstrual migraine. PMID: 28089731
  48. The results demonstrated that the rs3751592 A/G polymorphism of the CYP19A1 gene was associated with the incidence of Alzheimer disease in a Chinese Han population, which suggests that CYP19A1 rs3751592 is a predisposing genetic factor for Alzheimer disease. PMID: 27583919
  49. CYP19 Gene Polymorphism is associated with Breast Cancer. PMID: 27165202
  50. The data showed that the effect of Activin A on ESCs was partially abrogated by pretreatment with an inhibitor of ALK4 (the type I receptor, ActRIB) and Smad4-siRNA. Cumulatively, these data suggest that Activin A promotes the secretion of estradiol from ESCs by increasing the expression of P450arom via the ALK4-Smad pathway. These findings indicate the ALK4-Smad pathway may promote ectopic lesion survival and developmen PMID: 27833918

Show More

Hide All

Involvement in disease Aromatase excess syndrome (AEXS); Aromatase deficiency (AROD)
Subcellular Location Membrane, Peripheral membrane protein
Protein Families Cytochrome P450 family
Tissue Specificity Widely expressed, including in adult and fetal brain, placenta, skin fibroblasts, adipose tissue and gonads.
Database Links

HGNC: 2594

OMIM: 107910

KEGG: hsa:1588

STRING: 9606.ENSP00000260433

UniGene: Hs.260074


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1